Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naïve chronic hepatitis B patients

2019 ◽  
Vol 26 ◽  
pp. 59-68
Author(s):  
Qiran Zhang ◽  
Guojun Li ◽  
Yiqi Yu ◽  
Chao Qiu ◽  
Jianming Zheng ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Combination Therapy ◽  
Chronic Hepatitis B ◽  
Histological Response ◽  
Treatment Naïve

The partial virological response to Tenofovir monotherapy in naïve patients with chronic hepatitis B

2020 ◽  
pp. 1-12
Author(s):  
Habip Gedik ◽  
Muge Sonmezisik
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Partial Response ◽  
Combination Therapy ◽  
Chronic Hepatitis B ◽  
Antiviral Drug ◽  
Sustained Viral Response ◽  
Treatment Naïve ◽  
Tenofovir Alafenamide ◽  
Partial Virological Response

Abstract We report two treatment-naïve cases, a 26-year-old female patient and a 59-year-old male patient who were followed up for chronic hepatitis B (CHB) at the Department of Infectious Diseases and Clinical Microbiology. A partial response subsequent to 12 months of Tenofovir Disoproksil (TDF) monotherapy presumably due to an antiviral-drug resistance was noted. A sustained viral response with TDF (245 mg) or Tenofovir Alafenamide (TAF, 25 mg) + Entecavir (ETV, 1 mg) combination therapy was observed after failure with TDF monotherapy. A combination therapy with TDF (245 mg) or TAF (25 mg) +ETV (1 mg) is efficacious in naïve patients with a partial response to TDF monotherapy. Keywords: Chronic hepatitis B, Tenofovir, partial response, Entecavir, combination therapy

scholarly journals Beneficial Effects of Bushen Formula Combined with Enticavir on Chronic Hepatitis B Patients with Suboptimal Response to Enticavir by Regulating B-Cell Differentiation

2018 ◽  
Vol 48 (2) ◽  
pp. 633-643 ◽  
Author(s):  
Man Li ◽  
Zhen-Hua Zhou ◽  
Ting Bao ◽  
Xin Zhang ◽  
Xiao-Jun Zhu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
B Cells ◽  
Chinese Medicine ◽  
Hepatitis B ◽  
Combination Therapy ◽  
B Cell ◽  
Chronic Hepatitis B ◽  
Healthy Controls ◽  
Treatment Naïve ◽  
Symptom Complex

Background/Aims: To investigate the clinical effects of the combination therapy with Bushen Formula (BSF) plus enticavir (ETV) on chronic hepatitis B (CHB) patients with suboptimal response to ETV and explore the regulatory mechanisms of BSF on B cells-mediated humoral immunity. Methods: Sixty-four HBeAg-positive CHB patients with suboptimal response to ETV were enrolled, and were randomly assigned into control group (C-Group, placebo combined with ETV for 12 months) or treatment group (T-Group, BSF combined with ETV for 12 months). Serum samples from 57 treatment-naïve CHB patients and 15 healthy controls were collected. Serum HBV DNA levels were evaluated by real-time PCR. Characteristics of peripheral blood B-cell subtypes were analyzed by flow cytometry. Serum HBV markers and B cell-activating factor (BAFF) levels were detected by ELISA. Chinese medicine symptom complex score was evaluated and recorded. Results: After treatment, the rates of patients with a reduction of HBsAg > 0.5 log10 IU/ml or 1.0 log10 IU/ml and the rates of HBeAg clearance in T-Group were all higher than those in C-group, with no significant intergroup difference. Only in T-Group, Chinese medicine symptom complex score and the frequency of total B cells were significantly decreased, and the frequencies of Bm1, CD24+CD27-switched B cells and plasma cells were markedly increased after treatment compared with those before treatment. Compared with healthy controls, serum BAFF levels in treatment-naïve CHB patients were increased, and there was a significant positive correlation between serum BAFF and HBsAg levels. However, serum BAFF levels did not differ after treatment in T-Group and C-Group. Conclusions: The combination therapy with BSF plus ETV promotes the reduction of HBsAg level and the clearance of HBeAg in CHB patients with partial response to ETV through regulating the differentiation of B-cell subsets.

scholarly journals Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice

2014 ◽  
Vol 13 (3) ◽  
pp. 327-336 ◽  
Author(s):  
Ezequiel Ridruejo ◽  
Sebastián Marciano ◽  
Omar Galdame ◽  
María V. Reggiardo ◽  
Alberto E. Muñoz ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Clinical Practice ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Efficacy And Safety ◽  
Hepatitis B Treatment ◽  
Treatment Naïve

Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity

Hepatology ◽  
2005 ◽  
Vol 42 (5) ◽  
pp. 1028-1036 ◽  
Author(s):  
Eirini I. Rigopoulou ◽  
Deepak Suri ◽  
Shilpa Chokshi ◽  
Ivana Mullerova ◽  
Steven Rice ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Combination Therapy ◽  
Chronic Hepatitis B ◽  
Interleukin 12 ◽  
Immunological Activity

Autonomic impairment in treatment-naive patients with chronic hepatitis B and C infections

2021 ◽  
pp. 102928
Author(s):  
Chih-Cheng Huang ◽  
Keng-Liang Wu ◽  
Jia-Shou Liu ◽  
Yung-Yee Chang
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Treatment Naïve
Sign in / Sign up

Export Citation Format

Share Document